Telomir Pharmaceuticals Inc. Common Stock
TELO | NASDAQ
$1.26
+$0.02 (+1.61%)
Sep 22, 2026, 12:24 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a |
Operating Income | -10.54M | -12.24M | -3.94M | -854.15K | -138.13K |
Interest Income | 125.64K | 48K | n/a | n/a | n/a |
Pretax Income | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
Net Income | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
Selling & General & Admin | 8.1M | 9.64M | 600.19K | 20.94K | 11.64K |
Research & Development | 2.44M | 2.24M | 1.57M | 833.21K | 126.49K |
Other Expenses | n/a | 370.5K | 1.77M | n/a | n/a |
Operating Expenses | 10.54M | 12.24M | 3.94M | 854.15K | 138.13K |
Interest Expense | n/a | -4.34M | 1.64M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 10.54M | 12.24M | 3.94M | 854.15K | 138.13K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 31.65M | 29.54M | 29.61M | 29.61M | 29.61M |
Shares Outstanding (Diluted) | 31.65M | 29.54M | 29.61M | 29.61M | 29.61M |
EPS (Basic) | -0.33 | -0.56 | -0.44 | -0.03 | 0 |
EPS (Diluted) | -0.33 | -0.56 | -0.44 | -0.03 | 0 |
EBITDA | -10.41M | 48K | -11.43M | n/a | n/a |
EBIT | -10.41M | -12.19M | -11.43M | -854.15K | -138.13K |
Depreciation & Amortization | n/a | 12.24M | n/a | 854.15K | 138.13K |
Add to Watchlist
Select watchlists to add or remove TELO